Versantis Closes CHF 16M Series B Financing Round to Advance Clinical Development of Novel…
Versantis, a clinical-stage biotech company developing disruptive therapies for rare liver and pediatric diseases, today announces the successful completion of an oversubscribed CHF 16…
Read More...
Read More...
